Journal
ONCOIMMUNOLOGY
Volume 5, Issue 5, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2015.1116675
Keywords
Adoptive T cell transfer; cancer immunotherapy; chemokine receptor; CXCR3; T cell trafficking; tumor vessels
Categories
Funding
- NCI NIH HHS [R21 CA184433, P30 CA016056, R01 CA079765] Funding Source: Medline
- NIAID NIH HHS [R01 AI082039] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P30CA016056, R21CA184433, R01CA079765] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI082039] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Promising cancer immunotherapeutics depend on mobilization of cytotoxic T cells across tumor vascular barriers through mechanisms that are poorly understood. Recently, we discovered that the CXCR3 chemokine receptor uniquely functions as the master-regulator of cytotoxic CD8(+) T cell extravasation and tumor control despite the multiplicity of chemokines available in the tumor landscape.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
